<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Randomized trials for upper abdomen irradiation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Randomized trials for upper abdomen irradiation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Randomized trials for upper abdomen irradiation</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="10%"></colgroup><colgroup span="4" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Reference</td> <td class="subtitle1">Number of patients</td> <td class="subtitle1">Radiotherapy</td> <td class="subtitle1">Antiemetic</td> <td class="subtitle1">Complete response (percent)</td> <td class="subtitle1">Results</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Priestman<sup>1</sup></td> <td class="divider_bottom" rowspan="2">82</td> <td class="divider_bottom" rowspan="2">8-10 Gy single fraction</td> <td>OND (8 mg x 3/day PO for 5 days)</td> <td>97</td> <td class="divider_bottom" rowspan="2">OND better than MCP</td> </tr> <tr class="divider_bottom"> <td>MCP (10 mg x 3/day PO for 5 days)</td> <td>46</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Priestman<sup>2</sup></td> <td class="divider_bottom" rowspan="2">135</td> <td class="divider_bottom" rowspan="2">1.8 Gy/day for at least 5 fractions</td> <td>OND (8 mg x 3/day PO)</td> <td>61</td> <td class="divider_bottom" rowspan="2">OND better than MCP for vomiting</td> </tr> <tr class="divider_bottom"> <td>MCP (10 mg x 3/day PO)</td> <td>35</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Bey<sup>3</sup></td> <td class="divider_bottom" rowspan="4">50</td> <td class="divider_bottom" rowspan="4">At least 6 Gy single fraction</td> <td>DOL (0.3 mg/kg IV)</td> <td>100*</td> <td class="divider_bottom" rowspan="4">DOL better than placebo</td> </tr> <tr> <td>DOL (0.6 mg/kg IV)</td> <td>93*</td> </tr> <tr> <td>DOL (1.2 mg/kg IV)</td> <td>83*</td> </tr> <tr class="divider_bottom"> <td>Placebo</td> <td>54*</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Franzen<sup>4</sup></td> <td class="divider_bottom" rowspan="2">111</td> <td class="divider_bottom" rowspan="2">At least 1.7 Gy/day for ≥10 fractions</td> <td>OND (8 mg x 2/day PO)</td> <td>67</td> <td class="divider_bottom" rowspan="2">OND better than placebo</td> </tr> <tr class="divider_bottom"> <td>Placebo</td> <td>45</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Aass<sup>5</sup></td> <td class="divider_bottom" rowspan="2">23</td> <td class="divider_bottom" rowspan="2">2 Gy/day to 30 Gy in 15 fractions</td> <td>TRO (5 mg/day PO)</td> <td>91</td> <td class="divider_bottom" rowspan="2">TRO better than MCP</td> </tr> <tr class="divider_bottom"> <td>MCP (10 mg x 3/day PO)</td> <td>50</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Lanciano<sup>6</sup></td> <td class="divider_bottom" rowspan="2">260</td> <td>10-30 fractions</td> <td>GRAN (2 mg/day)</td> <td>57.5</td> <td class="divider_bottom" rowspan="2">GRAN better than placebo</td> </tr> <tr class="divider_bottom"> <td>(1.8-3 Gy/fraction)</td> <td>Placebo</td> <td>42</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Kirkbride<sup>7</sup></td> <td class="divider_bottom" rowspan="2">154</td> <td class="divider_bottom" rowspan="2">At least 5 fractions to minimum total dose of 20 Gy</td> <td>DEX (2 mg x 3/day PO for 5-7 days)</td> <td>70</td> <td class="divider_bottom" rowspan="2">DEX better than placebo</td> </tr> <tr class="divider_bottom"> <td>Placebo</td> <td>49</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Wong<sup>8</sup></td> <td class="divider_bottom" rowspan="2">211</td> <td class="divider_bottom" rowspan="2">≥15 fractions to the upper abdomen to a dose of 20 or more Gy</td> <td>OND (8 mg BID for 5 days) + placebo for 5 days</td> <td> <p>71<sup>¶</sup></p> 12<sup>Δ</sup></td> <td class="divider_bottom" rowspan="2">OND + DEX better than OND alone</td> </tr> <tr class="divider_bottom"> <td>OND (8 mg BID) + DEX (4 mg for 5 days)</td> <td> <p>78<sup>¶</sup></p> 23<sup>Δ</sup></td> </tr> <tr> <td rowspan="2">Mystakidou<sup>9</sup></td> <td rowspan="2">288</td> <td rowspan="2">Fractionated radiotherapy of moderate or high emetogenic potential</td> <td>TRO 5 mg daily starting 1 day before radiotherapy until 7 days after end of radiotherapy</td> <td rowspan="2">Incidence of vomiting was 2.19 times higher in rescue arm</td> <td rowspan="2">Prophylactic TRO better than rescue TRO</td> </tr> <tr> <td>TRO 5 mg on an as needed basis</td> </tr> </tbody></table></div><div class="graphic_footnotes">OND: ondansetron; PO: orally; MCP: metoclopramide; DOL: dolasetron; IV: intravenously; TRO: tropisetron; DEX: dexamethasone; BID: twice a day.<br/>* Complete plus major response.<br/>¶ Primary endpoint: CR day 1-5.<br/>Δ Secondary endpoint: CR day 1-15.</div><div class="graphic_reference">Reference: 

<ol>
<li>Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 1990; 2:71.</li>
<li>Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 1993; 5:358.</li>
<li>Bey P, Wilkinson PM, Resbeut M, et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 1996; 4:378.</li>
<li>Franzen L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996; 7:587.</li>
<li>Aass N, Håtun DE, Thoresen M, Fosså SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 1997; 45:125.</li>
<li>Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 2001; 19:763.</li>
<li>Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18:1960.</li>
<li>Wong RK, Paul N, Ding K, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006; 24:3458.</li>
<li>Mystakidou K, Katsouda E, Linou A, et al. Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients. Med Oncol 2006; 23:251.</li></ol></div><div id="graphicVersion">Graphic 82679 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
